GD2 CAR-NKT cells in neuroblastoma: early but very promising results of the ongoing study led by and Dr Metelitsa at . Great potential as an off-the-shelf platform!
In an interim analysis of a first-in-human phase 1 #clinicaltrial in patients with #neuroblastoma, highly pure GD2-specific CAR natural killer T cells were well-tolerated with no observed dose-limiting toxicities #NMEDclinical #Immunotherapy #Immunology